<DOC>
	<DOCNO>NCT00003411</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Motexafin gadolinium may increase effectiveness radiation therapy make tumor cell sensitive treatment . PURPOSE : Phase I trial study effectiveness radiation therapy plus motexafin gadolinium treat patient bile duct , gallbladder , pancreatic cancer remove surgically .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients With Bile Duct , Gallbladder , Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety toxicity motexafin gadolinium ( PCI-0120 ) administer concurrently radiotherapy patient locally advance unresectable pancreatic biliary tree tumor . II . Assess pharmacokinetics regimen patient . III . Assess tumor uptake PCI-0120 ( MRI signal characteristic ) patient . IV . Determine maximum tolerate dose PCI-0120 patient . V. Determine objective response ( radiologic criterion ) patient treat regimen . OUTLINE : This multicenter , dose-escalation study motexafin gadolinium ( PCI-0120 ) . Patients receive PCI-0120 IV 15 minute 3 time weekly concurrently external beam radiotherapy ( EBRT ) 5 day week 5.5 week . After completion EBRT PCI-0120 , patient may undergo radiotherapy boost 5 consecutive day . Cohorts 3-6 patient receive escalate dos PCI-0120 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . A total 6-12 patient treat recommended phase II dose . The recommended phase II dose define dose immediately precede MTD . Patients follow 4 week . PROJECTED ACCRUAL : A total 18-21 patient accrue study .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm locally advance , unresectable carcinoma biliary tree pancreas Metastatic disease allow case case basis provide follow criteria exists : Minimal low volume disease Need palliative radiotherapy primary tumor without motexafin gadolinium No requirement systemic therapy Measurable disease least 2 dimension No ascites require therapy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 No history glucose6phosphate dehydrogenase deficiency Hepatic : Bilirubin great 2.0 mg/dL AST ALT less 3 time upper limit normal Renal : Creatinine great 1.6 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history porphyria No active infection No physical psychological illness would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy primary site tumor Surgery : See Disease Characteristics At least 3 week since prior major surgery Other : At least 4 week since prior investigational drug No concurrent investigational antineoplastic drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>